Cart
sales@molnova.com
RLY-2608
CAS No. 2733573-94-7
RLY-2608( —— )
Catalog No. M37293 CAS No. 2733573-94-7
RLY-2608 is a selective mutant PI3Kα inhibitor that inhibits tumor growth in a PIK3CA mutant xenograft model.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 818 | In Stock |
|
| 5MG | 1017 | In Stock |
|
| 10MG | 1644 | In Stock |
|
| 25MG | 2374 | In Stock |
|
| 50MG | 3202 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRLY-2608
-
NoteResearch use only, not for human use.
-
Brief DescriptionRLY-2608 is a selective mutant PI3Kα inhibitor that inhibits tumor growth in a PIK3CA mutant xenograft model.
-
DescriptionRLY-2608 is a first-in-class allosteric mutant-selective inhibitor of PI3Ka.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorPI3K
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2733573-94-7
-
Formula Weight608.91
-
Molecular FormulaC29H14ClF5N6O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(C(=O)C1=CC(C(F)(F)F)=CC(F)=C1)C2=C3[C@@H](NC(=O)C3=CC(=C2)C4=C(C#N)N5C(C=C4)=NC=N5)C6=C(Cl)C=CC(F)=C6
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Andreas Varkaris, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia. Cancer Discov. 2023 Nov 2.?
molnova catalog
related products
-
Vps34 inhibitor PIK-...
Vps34 inhibitor PIK-III (PIK-III) is a potent, selective inhibitor of Vps34 with IC50 of 18 nM.
-
Gynostemma Extract
Gynostemma Extract is a saponins extract derived from the Gynostemma pentaphyllum.
-
PI-3065
A potent inhibitor of PI3K p110δ with IC50/Ki values of 5/1.5 nM respectively.
